Utilizing CyTOF analyses, we next determined the effect of SNDX-50469 treatment on fold-change in protein levels in two samples of phenotypically characterized, PD, CD34 + sorted AML progenitor cells, based on the low expression of CD11b, but high expression of CLEC12A, CD244, CD99, CD123, and CD33. The gene discussed is CD33; the disease is acute myeloid leukemia.